Treatment of HER2-positive early breast cancer: How to best balance efficacy and toxicity?
Authors:
- 11 July 2018
- journal article
- editorial
- Published by Hindawi Limited in The Breast Journal
- Vol. 24 (4) , 459-461
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- Health-Related Quality of Life With Adjuvant Docetaxel- and Trastuzumab-Based Regimens in Patients with Node-Positive and High-Risk Node-Negative, HER2-Positive Early Breast Cancer: Results from the BCIRG 006 StudyThe Oncologist, 2013
- Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysisSupportive Care in Cancer, 2012
- Adjuvant Trastuzumab in HER2-Positive Breast CancerNew England Journal of Medicine, 2011
- 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumoursEuropean Journal of Cancer, 2011
- Adjuvant Docetaxel for High-Risk, Node-Negative Breast CancerNew England Journal of Medicine, 2010
- Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?Supportive Care in Cancer, 2010
- Trastuzumab versus lapatinib: The cardiac side of the storyCancer Treatment Reviews, 2009
- Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735Journal of Clinical Oncology, 2009
- Herceptin and the Heart — A Molecular Modifier of Cardiac FailureNew England Journal of Medicine, 2006
- Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancersOncogene, 1999